CCR5 Antagonists (Maraviroc and Vicriviroc) CCR5 antagonists block viral binding to the CCR5 chemokine coreceptor. Several CCR5 antagonists have been tested in clinical trials. In August 2007, maraviroc was approved for use in multidrug-resistant patients with R5-only virus. A phase IIb/III trial of this agent in treatment-experienced patients has been reported.[4,5] A phase IIb/III study …
These are some contacts Silikon 1000 : https://www.derekjones.com or www.resderm.com or https://www.orentreich.com/ (use off label in the US) Bioalcamid in Canada (several cities) https://www.faceforward.ca/ or Mexico (monterrey)egarzaskin@yahoo.com (not FDA approved in the US yet) PMMA in Mexico (tijuana) luis_casavantes@msn.com ( product approved in the US: Artefill, but very expensive!) Sculptra : https://sculptra.com/US/Index.jsp (FDA approved for …
Facial Reconstruction Options in the Us- Sept 2007 Read More »
The Georgetown University Health Policy Institute has written A CONSUMER GUIDE FOR GETTING AND KEEPING HEALTH INSURANCE for each state and the District of Columbia — fifty-one in all. These Consumer Guides are available at this web site and will be updated periodically as changes in federal and state policy warrant. https://healthinsuranceinfo.net/ I hear this …
Health Insurance Resources for HIV Positive People (non ADAP) Read More »
The New Wave of HIV Drugs is Here For the first time in 10 years, HIV+ patients will have access to two new HIV drug classes. Patients with ongoing viral replication that have been failing current medicines will have a “second chance” to control their HIV by starting new drugs to which their virus has …
Positively Aware July/August 2007You’re Fired!Changing your doctor by Matt Sharp Donald Trump’s irritating voice rang in my ears as I stormed home from one of the most humiliating experiences as a “patient” in my 20 years of receiving HIV care. The details of the situation are not as important as the light bulb that went …
I am seeing a very strong trend of allowing pharmaceutical employees to speak to clinician and patient groups about their products in lectures set up by industry. I have attended many CME based and non CME lectures and I can say that I have hardly seen a neutral or unbiased lecture when a pharma employee …
Should pharmaceutical employees be allowed to lecture about their products? Read More »
